Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin for Lower Ureteral Stones > 6mm
NCT06381206Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Countries
- 1
- Sponsor
- Syrian Private University
- Modality
- Small Molecules
- Drugs
- silodosin
- Conditions
- ureteral stone
01
Overview
Phase 2, open-label trial of silodosin in ureteral stone, sponsored by Syrian Private University. Primary endpoints: Stone expulsion rate at 1 year and Time to stone expulsion at 1 year. Started Oct 2022; status: completed.
02
Design
- Study design
- Open-label
03
Who it enrols
Adults with a distal unilateral ureteral stone > 6mm, excluding those with severe hydronephrosis, single kidney, or bilateral stones.
04
Endpoints
Primary
Stone expulsion rate
Time to stone expulsion
Beyond the preview
Go deeper on NCT06381206.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381206.